Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)

Theodore Nicolaides, Kellie J. Nazemi, John Crawford, Lindsay Kilburn, Jane Minturn, Amar Gajjar, Karen Gauvain, Sarah Leary, Girish Dhall, Mariam Aboian, Giles Robinson, Janel Long-Boyle, Hechuan Wang, Annette M. Molinaro, Sabine Mueller, Michael Prados

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: BRAFV600E mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAFV600E kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) was to determine the recommended phase 2 dose (RP2D) and dose limiting toxicities (DLTs) in children < 18 years with recurrent or progressive BRAFV600E mutant brain tumors. Results: Nineteen eligible patients were enrolled. Eleven patients had received three or more prior therapies. Data reported are from the start of treatment for the first patient (April 30 2014) through August 31 2019. The RP2D was defined as 550 mg/m2 twice daily after DLT criteria adjustment for rash. Related grade ≥ 3 adverse events included secondary keratoacanthoma (n = 1); rash (n =16); and fever (n = 5). Subjects received a median of 23 cycles (range 3–63). Four patients remain on treatment. Centrally reviewed best radiographic responses included 1 complete response, 5 partial responses, and 13 stable disease. The steady-state area under the curve (AUC0-∞median) was 604 mg*h/L (range 329–1052). Methods: Vemurafenib was given starting at 550 mg/m2, twice daily which corresponds to the adult RP2D. Adverse events were graded using the NIH Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Central imaging review was performed. Pharmacokinetic sampling was performed. Conclusions: Vemurafenib has promising anti-tumor activity in recurrent BRAF V600E-positive brain tumors with manageable toxicity. A phase 2 study is ongoing (NCT01748149).

Original languageEnglish (US)
Pages (from-to)1942-1952
Number of pages11
JournalOncotarget
Volume11
Issue number21
DOIs
StatePublished - May 26 2020

Keywords

  • BRAF
  • Clinical trial
  • Pediatric glioma
  • Vemurafenib

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase I study of vemurafenib in children with recurrent or progressive BRAF<sup>V600E</sup> mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)'. Together they form a unique fingerprint.

Cite this